A detailed history of Partners Capital Investment Group, LLP transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Partners Capital Investment Group, LLP holds 88,770 shares of BMY stock, worth $5.23 Million. This represents 0.15% of its overall portfolio holdings.

Number of Shares
88,770
Previous 170,975 48.08%
Holding current value
$5.23 Million
Previous $8.85 Million 43.26%
% of portfolio
0.15%
Previous 0.15%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 31, 2025

SELL
$51.92 - $59.94 $4.27 Million - $4.93 Million
-82,205 Reduced 48.08%
88,770 $5.02 Million
Q3 2024

Nov 05, 2024

SELL
$39.66 - $51.75 $384,979 - $502,337
-9,707 Reduced 5.37%
170,975 $8.85 Million
Q2 2024

Aug 13, 2024

BUY
$40.25 - $52.99 $3.08 Million - $4.05 Million
76,420 Added 73.3%
180,682 $7.5 Million
Q1 2024

May 14, 2024

SELL
$47.98 - $54.4 $5.04 Million - $5.71 Million
-105,016 Reduced 50.18%
104,262 $5.65 Million
Q4 2023

Feb 12, 2024

BUY
$48.48 - $57.85 $2.86 Million - $3.41 Million
58,923 Added 39.19%
209,278 $10.7 Million
Q3 2023

Nov 14, 2023

SELL
$57.89 - $64.73 $195,147 - $218,204
-3,371 Reduced 2.19%
150,355 $8.73 Million
Q2 2023

Aug 14, 2023

SELL
$63.71 - $70.74 $3.99 Million - $4.43 Million
-62,572 Reduced 28.93%
153,726 $9.83 Million
Q1 2023

May 15, 2023

BUY
$65.71 - $74.53 $2.56 Million - $2.9 Million
38,887 Added 21.92%
216,298 $15 Million
Q4 2022

Feb 14, 2023

BUY
$68.48 - $81.09 $4.5 Million - $5.32 Million
65,660 Added 58.76%
177,411 $12.8 Million
Q3 2022

Nov 14, 2022

BUY
$0.13 - $76.84 $14,527 - $8.59 Million
111,751 New
111,751 $7.94 Million
Q2 2021

Aug 16, 2021

SELL
$61.91 - $67.42 $331,651 - $361,168
-5,357 Closed
0 $0
Q2 2020

Aug 12, 2020

BUY
$54.82 - $64.09 $293,670 - $343,330
5,357 New
5,357 $315,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $125B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Partners Capital Investment Group, LLP Portfolio

Follow Partners Capital Investment Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Partners Capital Investment Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Partners Capital Investment Group, LLP with notifications on news.